Related Experiment Video

Updated: Feb 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Cell type-specific pharmacological kinase inhibition for cancer chemoprevention

Manjeet Deshmukh1, Shigeki Nakagawa2, Takaaki Higashi2

  • 1Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Nanomedicine : Nanotechnology, Biology, and Medicine
|November 22, 2017
PubMed

Insights

Targeting cancer-driving cells specifically with drugs enhances effectiveness and reduces toxicity. This novel approach improves precision cancer chemoprevention by delivering molecular-targeted agents directly to effector cells, like hepatic myofibroblasts.

Area of Science:

  • Oncology
  • Nanomedicine
  • Hepatology

Background:

  • Non-toxic agents often lack efficacy in chemoprevention.
  • Hepatic myofibroblasts contribute to liver fibrosis, cirrhosis, and liver cancer.
  • Targeting specific cell types is crucial for effective and safe cancer chemoprevention.

Purpose of the Study:

  • To develop a strategy for effective cancer chemoprevention by delivering molecular-targeted agents specifically to effector cells.
  • To investigate the efficacy of cell type-specific kinase inhibition in a rat model of cirrhosis-driven liver cancer.

Main Methods:

  • Utilized a nanoparticle-based delivery system to target erlotinib (an epidermal growth factor receptor inhibitor) to hepatic myofibroblasts.
  • Targeted platelet-derived growth factor receptor-beta, uniquely expressed on hepatic myofibroblasts.
  • Administered the targeted agent in a rat model of cirrhosis-driven liver cancer.

Main Results:

  • Myofibroblast-targeted delivery of erlotinib reduced tumor burden to 21%.
  • Systemic administration of erlotinib alone reduced tumor burden to 31%.
  • Targeted delivery achieved greater efficacy with a reduced erlotinib dose and less hepatocyte damage.

Conclusions:

  • Cell type-specific kinase inhibition is a viable strategy for precision cancer chemoprevention.
  • Nanoparticle-mediated targeted delivery enhances the safety and efficacy of chemopreventive agents.
  • This approach offers a promising method for overcoming the challenge of achieving sufficient potency while minimizing toxicity.
Keywords:
Cancer chemopreventionEpidermal growth factorKinase inhibitorLiver cancerNanoparticle

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.6K